List of Excipients in Branded Drug GENTAMICIN SULFATE IN SODIUM CHLORIDE

Generic Drugs Containing GENTAMICIN SULFATE IN SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Baxter Healthcare Corporation	gentamicin sulfate	0338-0507	SODIUM CHLORIDE
Baxter Healthcare Corporation	gentamicin sulfate	0338-0507	SODIUM HYDROXIDE
Baxter Healthcare Corporation	gentamicin sulfate	0338-0507	SULFURIC ACID

What are the Most Frequently-Used Excipients in GENTAMICIN SULFATE IN SODIUM CHLORIDE?

# Of NDCs	Excipient
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	SULFURIC ACID

Gentamicin Sulfate in Sodium Chloride: Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: September 24, 2026

Gentamicin sulfate in sodium chloride is a mature generic injectable with limited patent exclusivity and substantial manufacturing barriers. The commercial opportunity is concentrated in ready-to-use presentations, preservative-free packaging, pediatric and neonatal dosing formats, supply reliability, and improved container-closure systems. Sodium chloride is the principal excipient and cannot be treated as a simple commodity input because concentration, osmolality, pH, compatibility, and extractables affect product performance.

What is gentamicin sulfate in sodium chloride?

Gentamicin sulfate in sodium chloride is an intravenous infusion product containing gentamicin sulfate dissolved in 0.9% sodium chloride injection. Gentamicin is an aminoglycoside antibacterial used against susceptible serious Gram-negative infections and selected synergistic indications involving Gram-positive organisms.[1]

The product is generally supplied as a sterile, preservative-free solution in a flexible bag or other single-dose container. The formulation typically contains:

Component	Function
Gentamicin sulfate	Active antibacterial ingredient
Sodium chloride	Tonicity agent and infusion vehicle
Water for Injection	Solvent
pH adjustment system, where applicable	Controls solution stability and product performance

Gentamicin sulfate is a mixture of closely related aminoglycoside components rather than a single chemically uniform small molecule. That characteristic affects assay, impurity control, potency measurement, and comparability between suppliers.[2]

What excipient strategy is used for gentamicin sulfate in sodium chloride?

The core excipient strategy is minimal formulation. Sodium chloride provides isotonicity while avoiding unnecessary excipients that could increase compatibility, toxicity, or regulatory risk.

Why sodium chloride is the preferred vehicle

A 0.9% sodium chloride vehicle is familiar to hospitals, compatible with standard intravenous administration practices, and widely supported by established pharmaceutical infrastructure. It also reduces the need for a separate dilution step before administration.

The key formulation controls are:

• Sodium chloride concentration and final osmolality
• Gentamicin sulfate concentration
• Solution pH
• Particulate and visible impurity limits
• Container compatibility
• Stability during storage and administration
• Compatibility with infusion equipment and co-administered medicines

The label for gentamicin sulfate injection generally identifies pH control and compatibility restrictions as important product attributes.[1] Aminoglycosides can be physically or chemically incompatible with beta-lactam antibiotics when mixed directly, so the formulation and label should direct separate administration where required.[1]

What excipients should be avoided?

An expanded excipient system may create more regulatory and commercial risk than value. Potentially unnecessary additions include:

• Preservatives in products intended for intravenous use
• Surfactants that may affect tolerability or container interaction
• Chelating agents without a demonstrated stability need
• Buffers that alter gentamicin stability or compatibility
• Antioxidants that are not justified by degradation data
• Novel solubilizers that complicate safety review

A preservative-free, single-dose product is generally the strongest baseline for hospital use. It aligns with parenteral safety expectations and avoids preservative exposure in neonates and other vulnerable patients.

What formulations are protected by gentamicin sulfate patents?

No active-ingredient patent estate comparable to that of a recently approved branded drug protects gentamicin sulfate in sodium chloride. Gentamicin has been marketed for decades, and the principal commercial barriers are manufacturing, quality, regulatory compliance, and supply execution rather than composition-of-matter exclusivity.

Patent and exclusivity profile

Protection category	Commercial position
Composition-of-matter patent	Expired or commercially immaterial
Basic gentamicin formulation patent	No material active exclusivity identified
Method-of-use patent	No significant modern exclusivity expected for established labeled uses
Orange Book-listed patents	Product-specific review required; no material patent barrier is expected for the mature generic category
FDA new-drug exclusivity	Not expected for long-established gentamicin products
Manufacturing know-how	Important, particularly for sterile filling, impurity control, and supplier qualification
Container-closure technology	Potential source of narrow, product-specific protection

The most defensible intellectual property for a new entrant would likely involve a specific presentation, container system, manufacturing process, stability profile, or device configuration rather than gentamicin itself.

What is the FDA regulatory status of gentamicin sulfate in sodium chloride?

Gentamicin sulfate in sodium chloride is regulated as a prescription sterile injectable. Generic versions generally proceed through the abbreviated new drug application pathway when the reference product and dosage form are eligible for ANDA approval.[3]

The regulatory burden includes:

• Demonstration of pharmaceutical equivalence
• Sterility assurance
• Bacterial endotoxin control
• Assay and impurity specifications
• Particulate matter testing
• Container-closure integrity
• Stability data
• Manufacturing process validation
• Compatibility data for the labeled route and presentation

For a parenteral solution, bioequivalence requirements may be less burdensome than for an oral product when the product is equivalent in active ingredient, dosage form, strength, route, and excipient composition or when differences are adequately justified under FDA requirements.[3]

What is the Orange Book status?

The Orange Book identifies approved drug products and applicable patent or exclusivity information. For a mature gentamicin injectable, the commercial analysis should focus on the specific applicant, strength, dosage form, and reference-listed drug rather than assuming that all gentamicin products have identical regulatory status.[4]

The practical conclusion is that Orange Book-listed patent risk is likely to be limited. Approval and market success depend more heavily on manufacturing reliability, product availability, and procurement access than on clearing a branded patent thicket.

When does gentamicin sulfate in sodium chloride lose exclusivity?

The product has already passed the relevant period of new-drug and basic patent exclusivity associated with its original development. Current products compete as mature generic injectables.

The relevant commercial timeline is therefore:

Milestone	Timing and impact
Original gentamicin development	Historical; basic exclusivity has expired
Generic injectable entry	Established market with multiple suppliers
Current market access	Driven by ANDA approval and manufacturing capacity
Future loss of exclusivity	Not the principal market issue
Current competitive risk	Supply interruption, contract loss, price pressure, and facility observations

This structure creates a low-patent, high-execution market. A company does not need to wait for a major patent expiration to enter, but it must secure validated sterile manufacturing and reliable active pharmaceutical ingredient supply.

What generic entry risks exist?

Generic entry risk is high from a price perspective and moderate from a technical execution perspective.

Commercial risks

Gentamicin sulfate in sodium chloride is vulnerable to:

• Multiple-source generic competition
• Hospital group purchasing organization price reductions
• Tender-based purchasing
• Substitution by other aminoglycosides or broader-spectrum agents
• Low annual treatment value per unit
• Customer preference for suppliers with reliable fill rates
• Margin compression in standard 100 mL presentations

The product may still have attractive economics when shortages reduce the number of available suppliers. The FDA Drug Shortages database and American Society of Health-System Pharmacists shortage reporting are important commercial indicators for injectable supply conditions.[5,6]

Technical risks

The principal technical risks are:

• Variability in gentamicin sulfate potency and impurity profile
• Adsorption or interaction with container materials
• Particulate formation
• Inadequate container-closure integrity
• Sterility failures
• Poor stability at temperature extremes
• Incompatibility with administration sets
• Inconsistent supply of qualified gentamicin sulfate API

These risks make the product more difficult to manufacture than its simple ingredient list suggests.

What commercial opportunities exist for excipient and presentation innovation?

The strongest opportunities involve convenience, supply reliability, and risk reduction rather than novel pharmacology.

Ready-to-use infusion bags

A ready-to-use product reduces pharmacy compounding, preparation time, and medication-error risk. Hospitals may value a premixed bag when it is competitively priced and consistently available.

Potential differentiators include:

• Standardized concentrations
• Clear labeling of total gentamicin content
• Bar-code compatibility
• Tear-open packaging
• Improved overwrap protection
• Extended shelf life
• Multiple bag sizes for adult and pediatric use

Low-volume pediatric and neonatal presentations

Neonatal and pediatric patients require weight-based dosing and careful renal monitoring. Low-volume presentations may reduce waste and simplify preparation. The formulation must preserve the same sterile, preservative-free profile while controlling dosing accuracy.

The opportunity is commercially meaningful but technically sensitive. Small-volume products require strong control of fill accuracy, extractables, particulate burden, and labeling clarity.

Container-closure improvements

The container may provide a more practical differentiation point than the excipient composition. Candidate systems include:

• Polyolefin flexible bags
• Non-DEHP materials where clinically and commercially appropriate
• Improved ports and administration connections
• Low-extractables elastomers
• Clearer overwrap and tamper evidence
• Packaging designed for automated pharmacy systems

Any container change requires extractables and leachables assessment, compatibility testing, stability studies, and container-closure integrity validation.[7]

Extended stability and distribution

A longer labeled shelf life can reduce inventory write-offs and support national distribution. The stability program should assess:

• Gentamicin potency
• Sulfate-related impurities
• Degradation products
• pH drift
• Osmolality
• Color and clarity
• Subvisible particles
• Container interaction
• Freeze-thaw and temperature excursion effects

Extended stability has direct procurement value when hospitals are managing shortages or maintaining emergency stock.

How strong is the patent estate for gentamicin sulfate in sodium chloride?

The patent estate is weak for the active ingredient and stronger only where a company develops a specific technical improvement.

IP asset	Expected strength
Gentamicin composition patent	Low; historical rights have expired
Sodium chloride vehicle	None as a basic formulation concept
Standard premixed bag	Low unless tied to a novel technical configuration
Novel container system	Moderate if claims are narrow and supported by performance data
Stability-enhancing formulation	Moderate, but must show unexpected technical benefit
Manufacturing process	Moderate; enforcement may be difficult if process claims are not observable
Pediatric presentation	Low to moderate, depending on technical features
Digital dosing or administration system	Potentially moderate, subject to patent quality and adoption

A company should pursue trade secrets and process control alongside patents. Sterile manufacturing parameters, supplier qualification methods, impurity-control strategies, and filling operations may provide more durable value than broad formulation claims.

Which companies are challenging the market?

The market is supplied by established generic and injectable manufacturers rather than a single dominant innovator. Relevant competitor groups include:

• Large generic pharmaceutical companies
• Hospital injectable specialists
• Contract manufacturing organizations
• Regional suppliers
• Authorized distributors and shortage-focused suppliers

Competitive assessment should compare FDA approval status, current availability, labeled concentrations, container format, manufacturing site, historical shortage record, and hospital contract coverage. Product availability is often more important than nominal approved capacity.

What patent litigation affects gentamicin sulfate in sodium chloride?

No material branded-patent litigation is expected to define the current market for this mature injectable category. Litigation risk is more likely to arise from:

• ANDA certification disputes involving a specific listed patent
• Manufacturing-process patents
• Container or connector patents
• Trade-secret disputes
• Contract manufacturing disagreements
• Product liability claims
• Sterility or recall-related enforcement

A Paragraph IV challenge would be commercially relevant only if an Orange Book-listed patent covered a particular reference product or presentation. For a long-established gentamicin sodium chloride product, the probability of a significant patent-driven launch delay is low relative to ordinary ANDA review and manufacturing readiness.

How does gentamicin sulfate in sodium chloride compare with competing antibiotics?

Attribute	Gentamicin sulfate in sodium chloride	Tobramycin injection	Amikacin injection
Drug class	Aminoglycoside	Aminoglycoside	Aminoglycoside
Market maturity	Very mature	Mature	Mature
Primary commercial advantage	Low cost and established use	Clinical familiarity in selected settings	Activity against some resistant organisms
Patent risk	Low	Low	Low
Toxicity monitoring	Renal and auditory	Renal and auditory	Renal and auditory
Formulation opportunity	Premixed, preservative-free, pediatric formats	Similar	Similar
Price pressure	High	High	Moderate to high
Differentiation potential	Supply and presentation	Clinical niche and supply	Spectrum and supply

Gentamicin remains commercially relevant where clinicians require an established, low-cost aminoglycoside and susceptibility data support its use. It competes with newer agents on safety, resistance, and stewardship considerations rather than patent status.

What licensing deals are relevant?

Licensing value is likely to arise from manufacturing and distribution arrangements rather than active pharmaceutical ingredient rights. Potential transaction structures include:

• In-licensing of an approved ANDA
• Contract manufacturing and supply agreements
• Regional commercialization rights
• Hospital tender partnerships
• API supply and dual-sourcing agreements
• Co-development of ready-to-use presentations
• Authorized generic arrangements

A licensee should prioritize validated sterile capacity, shortage performance, regulatory history, and supply continuity. A nominally attractive product with repeated manufacturing interruptions has limited strategic value.

What is the revenue exposure?

Revenue exposure is generally volume-driven and price-sensitive. The largest commercial variables are:

1. Annual unit demand.
2. Average selling price by strength and container size.
3. Hospital contract penetration.
4. Gross margin after sterile manufacturing and distribution costs.
5. Shortage-related price increases.
6. Product withdrawal or supply interruption risk.

A standard presentation may generate modest revenue per unit but can support recurring institutional demand. Higher-value opportunities may come from differentiated packaging, low-volume pediatric products, or supply contracts where reliability commands a premium.

Key Takeaways

• Gentamicin sulfate in sodium chloride is a mature generic injectable with minimal active-ingredient patent risk.
• Sodium chloride is the central excipient and provides a simple, hospital-compatible vehicle.
• Preservative-free, ready-to-use products are the strongest baseline formulation strategy.
• Commercial differentiation is more likely through packaging, stability, pediatric dosing, and supply reliability than through new excipients.
• The key technical barriers are sterile processing, API quality, impurity control, container compatibility, and stability.
• Paragraph IV and branded-patent risks are limited compared with ordinary ANDA, manufacturing, and procurement risks.
• The best licensing targets are approved products, sterile manufacturing capacity, regional distribution rights, and reliable gentamicin API supply.
• Revenue potential depends on institutional contracts, shortage conditions, and production continuity.

FAQs

Is sodium chloride the only important excipient in gentamicin sulfate injection?

It is the principal formulation excipient, but water quality, pH control, container materials, and packaging components also affect product quality and regulatory performance.

Can gentamicin sulfate injection contain preservatives?

Intravenous gentamicin products are generally positioned as preservative-free, single-dose preparations. Preservatives require a clear safety and regulatory justification and may be unsuitable for sensitive patient populations.

Is a premixed gentamicin bag patentable?

A standard gentamicin solution in 0.9% sodium chloride is unlikely to support broad patent protection. Patentability may exist for a specific container, stability solution, administration system, or manufacturing process with demonstrated technical advantages.

What is the main regulatory risk for a new gentamicin injectable?

The main risks are sterile manufacturing failure, particulate contamination, container-closure defects, inadequate stability, and API variability rather than clinical novelty.

Can gentamicin sulfate in sodium chloride support a premium price?

A premium is more defensible for reliable ready-to-use supply, pediatric or low-volume formats, extended stability, automated pharmacy compatibility, or a documented shortage-resilient supply chain.

References

1. DailyMed. (2024). Gentamicin sulfate injection, solution: Prescribing information. U.S. National Library of Medicine.

2. United States Pharmacopeial Convention. (2024). USP-NF monograph: Gentamicin sulfate. Rockville, MD: United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA.

5. U.S. Food and Drug Administration. (2024). Drug shortages. Silver Spring, MD: FDA.

6. American Society of Health-System Pharmacists. (2024). Drug shortages resource center. Bethesda, MD: ASHP.

7. U.S. Food and Drug Administration. (1999). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. Silver Spring, MD: FDA.